Document is current
Any future updates will be listed below
-
Authors
Helby, Jens https://orcid.org/0000-0002-1876-8187
Mottelson, Mathis https://orcid.org/0000-0001-8736-2618
Bojesen, Stig Egil https://orcid.org/0000-0002-4061-4133
Nordestgaard, Børge Grønne https://orcid.org/0000-0002-1954-7220
Faurschou, Mikkel
Petersen, Jesper https://orcid.org/0000-0001-6116-5114
Ellervik, Christina https://orcid.org/0000-0002-3088-4375
Warny, Marie
Glenthøj, Andreas https://orcid.org/0000-0003-2082-0738
- License Information
-
More Information
Article History
Received: 22 May 2025
Accepted: 18 March 2026
First Online: 7 April 2026
Competing interests
: The authors declare the following competing interests: A.G. received a research grant from Novo Nordisk for the submitted work. Without direct relation to the submitted work: A.G. received research funding from Agios, Bristol Myers Squibb, Novo Nordisk and Sanofi, and payment for consultancy work and/or advisory board participation from Agios, Vertex Pharmaceuticals, Pharmacosmos, Novo Nordisk, and Disc Medicine; J.H. received research funding, payment for advisory board participation, and a conference travel grant from Sanofi and payment for advisory board participation from Disc Medicine. C.E. is partly funded by the Laboratory Medicine Endowment Fund at Boston Children’s Hospital, USA. All other authors declare no relevant competing interests.
